Hyaluronidase

This drug entry is a stub and has not been fully annotated. It is scheduled to be annotated soon.

Identification

Logo pink
Are you a
new drug developer?
Contact us to learn more about our customized products and solutions.
Logo pink
Stay in the know!
As part of our commitment to providing the most up-to-date drug information, we will be releasing #DrugBankUpdates with our newly added curated drug pages.
#DrugBankUpdates
Name
Hyaluronidase
Accession Number
DB14740
Type
Biotech
Groups
Approved
Biologic Classification
Protein Based Therapies
Other protein based therapies
Description
Not Available
Protein chemical formula
Not Available
Protein average weight
Not Available
Sequences
Not Available
Synonyms
  • Hialuronidasa
  • Hyaluronidase
  • Hyaluronidase (bovine)
  • Hyaluronidase bovine
  • Hyaluronidase, bovine
  • Hyaluronidasum
  • Hyaluronoglucosaminidase
Prescription Products
NameDosageStrengthRouteLabellerMarketing StartMarketing End
AmphadaseInjection150 [USP'U]/1mLSubcutaneousAmphastar Pharmaceuticals, Inc.2004-10-26Not applicableUs
HydaseInjection, solution150 [USP'U]/1mLInfiltration; Interstitial; Intramuscular; Intraocular; Retrobulbar; SubcutaneousAkorn, Inc.2015-11-05Not applicableUs
Wydase Inj 150unit/mlLiquidInfiltration; SubcutaneousWyeth Ltd.1954-12-311996-09-10Canada
Wydase Injection Liq 150 Units/mlLiquidInfiltration; SubcutaneousWyeth Ayerst Canada Inc.1994-12-312002-06-10Canada
Additional Data Available
  • Application Number
    Application Number

    A unique ID assigned by the FDA when a product is submitted for approval by the labeller.

    Learn more
  • Product Code
    Product Code

    A governmentally-recognized ID which uniquely identifies the product within its regulatory market.

    Learn more
Mixture Products
NameIngredientsDosageRouteLabellerMarketing StartMarketing End
Rituxan HycelaHyaluronidase (2000 U/1mL) + Rituximab (120 mg/1mL)Injection, solutionSubcutaneousGenentech, Inc.2017-06-22Not applicableUs
Rituxan HycelaHyaluronidase (2000 U/1mL) + Rituximab (120 mg/1mL)Injection, solutionSubcutaneousGenentech, Inc.2017-06-22Not applicableUs
Categories
UNII
8KOG53Z5EM
CAS number
9001-54-1

Pharmacology

Indication
Not Available
Pharmacodynamics
Not Available
Mechanism of action
Not Available
Additional Data Available
Adverse Effects

Comprehensive structured data on known drug adverse effects with statistical prevalence. MedDRA and ICD10 ids are provided for adverse effect conditions and symptoms.

Learn more
Additional Data Available
Contraindications

Structured data covering drug contraindications. Each contraindication describes a scenario in which the drug is not to be used. Includes restrictions on co-administration, contraindicated populations, and more.

Learn more
Additional Data Available
Blackbox Warnings

Structured data representing warnings from the black box section of drug labels. These warnings cover important and dangerous risks, contraindications, or adverse effects.

Learn more
Absorption
Not Available
Volume of distribution
Not Available
Protein binding
Not Available
Metabolism
Not Available
Route of elimination
Not Available
Half life
Not Available
Clearance
Not Available
Toxicity
Not Available
Affected organisms
Not Available
Pathways
Not Available
Pharmacogenomic Effects/ADRs
Not Available

Interactions

Drug Interactions
This information should not be interpreted without the help of a healthcare provider. If you believe you are experiencing an interaction, contact a healthcare provider immediately. The absence of an interaction does not necessarily mean no interactions exist.
Not Available
Food Interactions
Not Available

References

General References
Not Available
External Links
Wikipedia
Hyaluronidase
ATC Codes
B06AA03 — Hyaluronidase

Clinical Trials

Clinical Trials
PhaseStatusPurposeConditionsCount
0Active Not RecruitingBasic ScienceDrug Safety1
0CompletedSupportive CareAddition of Hyalase to Local Anesthetic in Scalp Block1
0CompletedTreatmentType 1 Insulin-Dependent Diabetes Mellitus1
1CompletedTreatmentDehydration / Difficult Intravenous Access / Disaster Medicine1
1CompletedTreatmentDermal Filler1
1CompletedTreatmentType 1 Insulin-Dependent Diabetes Mellitus1
1RecruitingTreatmentBurkitt's Lymphoma / Castleman's Disease, Multicentric / CD20 Positive / HHV8-Positive Multicentric Castleman Disease / Kaposi s Sarcoma (KS) / KSHV-associated Multicentric Castleman Disease / Lymphoma, Large B-Cell, Diffuse (DLBCL)1
2CompletedScreeningAllergic Skin Reaction1
2CompletedTreatmentBreast Cancer1
2CompletedTreatmentDehydration1
2CompletedTreatmentPsoriasis1
2Not Yet RecruitingTreatmentMuscle Spasticity1
2RecruitingTreatmentChronic Lymphocytic Leukaemia (CLL)1
2RecruitingTreatmentCutaneous Melanoma, Stage III / Cutaneous Melanoma, Stage IV / Stage III Melanoma / Stage IIIA Skin Melanoma / Stage IIIB Skin Melanoma / Stage IIIC Skin Melanoma / Stage IV Skin Melanoma / Unresectable Melanoma1
2RecruitingTreatmentMantle Cell Lymphoma (MCL)1
3CompletedPreventionCardiovascular Heart Disease / Coronary Heart Disease (CHD) / Heart Diseases / Myocardial Infarction / Myocardial Ischemia1
3CompletedTreatmentRetinopathy, Diabetic / Vitreous Hemorrhage1
4CompletedOtherCardiac Output / Dehydration / Pediatrics1
4CompletedSupportive CareQuality of Ocular Akinesia (Onset and Duration)1
4CompletedTreatmentCardiac Dysrhythmia1
Not AvailableCompletedSupportive CareNalbuphine as an Adjuvant to L. A in Peribulbar Block for Cataract Surgery1
Not AvailableCompletedTreatmentHerniated Lumbar Disc1
Not AvailableNot Yet RecruitingDiagnosticIntraocular Pressure Low1
Not AvailableRecruitingPreventionPostoperative pain1
Not AvailableRecruitingTreatmentTreatment Resistant Carpal Tunnel in RA Patients1

Pharmacoeconomics

Manufacturers
Not Available
Packagers
Not Available
Dosage forms
FormRouteStrength
InjectionSubcutaneous150 [USP'U]/1mL
Injection, solutionInfiltration; Interstitial; Intramuscular; Intraocular; Retrobulbar; Subcutaneous150 [USP'U]/1mL
Injection, solutionSubcutaneous
LiquidInfiltration; Subcutaneous
Prices
Not Available
Patents
Not Available

Properties

State
Not Available
Experimental Properties
Not Available

Taxonomy

Description
Not Available
Kingdom
Organic Compounds
Super Class
Organic Acids
Class
Carboxylic Acids and Derivatives
Sub Class
Amino Acids, Peptides, and Analogues
Direct Parent
Peptides
Alternative Parents
Not Available
Substituents
Not Available
Molecular Framework
Not Available
External Descriptors
Not Available

Drug created on February 27, 2019 16:11 / Updated on November 02, 2019 03:26